Meningioma Pipeline Analysis Report 2026

Report Coverage

The Meningioma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into meningioma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for meningioma. The meningioma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The meningioma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with meningioma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to meningioma.

Read more about this report - Request a Free Sample

Meningioma Pipeline Outlook

The meningioma pipeline outlook reflects a gradual shift beyond conventional management approaches, which primarily rely on surgical resection and radiotherapy, with limited systemic treatment options for recurrent or high-grade disease. Growing molecular insights are driving the development of targeted, radioligand, and novel delivery-based therapies within the clinical pipeline.

Meningioma treatment is evolving as clinical momentum continues despite the absence of recent drug approvals. In March 2025, pipeline momentum was underscored as NeOnc Technologies reported encouraging Phase I/II clinical outcomes for its intranasal candidate NEO100, while the EORTC initiated the LUMEN-1 Phase II trial evaluating ¹⁷⁷Lu-DOTATATE in recurrent meningioma. These developments highlight increasing innovation and sustained clinical progress despite the absence of recent drug approvals.

Meningioma Epidemiology

Meningiomas are the most common primary central nervous system tumors, accounting for approximately 37-38% of all primary CNS tumors and about 50% of benign CNS tumors worldwide. Incidence increases with age, with a median age at diagnosis around 66 years and a female-to-male ratio of roughly 2.3:1, reflecting hormonal and genetic influences. Age-adjusted incidence ranges from 1.8 to 13 per 100,000 persons annually, and prevalence in the United States is ~97.5 per 100,000, equating to more than 170,000 individuals living with meningioma. Risk factors include ionizing radiation and inherited conditions such as NF2.

Meningioma – Pipeline Therapeutic Assessment

Meningioma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total meningioma clinical trials, indicating a strong focus on mid-stage development and proof-of-concept studies within the overall pipeline landscape. Phase-wise distribution is phase II (64%), phase I (22%), and early phase I (7%), reflecting comparatively limited late-stage development activity in the current meningioma clinical pipeline.

Meningioma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the meningioma pipeline analysis include small molecules, natural metabolites, and monoclonal antibodies. The meningioma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for meningioma. In August 2024, NeOnc Technologies announced the start of patient enrolment for its Phase 2 clinical trial of NEO100-02™, a novel intranasal formulation targeting residual, progressive, or recurrent high-grade meningioma. The study, conducted under FDA Fast-Track, Orphan Drug, and IND status, aims to evaluate the safety and preliminary biological effects of the candidate, leveraging its unique delivery method designed to overcome the blood-brain barrier.

Meningioma Clinical Trials – Key Players

The EMR report for the meningioma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed meningioma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in meningioma clinical trials:

• Novartis
• Neonc Technologies, Inc.
• Heron Neutron Medical Corp.
• Shanghai Runshi Pharmaceutical Technology Co., Ltd
• AstraZeneca
• Eli Lilly and Company
• GlaxoSmithKline

Meningioma – Emerging Drugs Profile

Key Questions Answered in the Meningioma Pipeline Insight Report

• Which companies/institutions are leading the meningioma drug development?
• Which company is leading the meningioma pipeline development activities?
• What is the current meningioma commercial assessment?
• What are the opportunities and challenges present in the meningioma pipeline landscape?
• What is the efficacy and safety profile of meningioma pipeline drugs?
• Which company is conducting major trials for meningioma drugs?
• Which companies/institutions are involved in meningioma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in meningioma?

Reasons To Buy This Report

The meningioma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for meningioma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into meningioma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Brain Tumor Treatment Market

Cancer Therapeutics Market